Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

208
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
208
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

155
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
155
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

397
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
397
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

234
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
234
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

133
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin.

Molecular pharmaceutics·2026
Same author

New Frontiers of Drug Development Through the Use of New Approach Methodologies.

The AAPS journal·2026
Same author

Correction to: Considerations in Kp,uu,brain-based Strategy for Selecting CNS-targeted Drug Candidates with Sufficient Target Coverage and Substantial Pharmacodynamic Effect.

The AAPS journal·2026
Same author

Proposed Meropenem Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Bacteria Isolated From Dogs.

Journal of veterinary pharmacology and therapeutics·2026
Same author

A Top-Down Physiologically Based Pharmacokinetic Modeling Approach to Explore Unexpected Bio-inequivalence of Experimental Oral Formulations in Dogs.

Pharmaceutical research·2026
Same author

Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
13:17

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

Published on: March 6, 2015

28.9K

A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A

Charlotte Cross1, Marilyn N Martinez2, Devendra Pade1

  • 1Certara UK Ltd., Certara Predictive Technologies, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, UK.

The AAPS Journal
|June 2, 2025
PubMed
Summary
This summary is machine-generated.

A new physiologically based pharmacokinetic (PBPK) model accurately predicts loperamide drug levels in Collies. This model accounts for genetic variations in the multidrug resistance 1 (Mdr1) gene, improving drug safety predictions in this breed.

Keywords:
Collie modelIVIVE-PBPKMdr1a mutationP-glycoproteinSIVA toolkitSimcyp dog simulator

More Related Videos

Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
11:11

Canine Intestinal Organoids in a Dual-Chamber Permeable Support System

Published on: March 2, 2022

3.8K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Related Experiment Videos

Last Updated: Sep 19, 2025

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
13:17

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

Published on: March 6, 2015

28.9K
Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
11:11

Canine Intestinal Organoids in a Dual-Chamber Permeable Support System

Published on: March 2, 2022

3.8K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Veterinary Pharmacology
  • Computational Biology

Background:

  • Loperamide is a substrate for P-glycoprotein (P-gp), encoded by the multidrug resistance 1 (Mdr1) gene.
  • Genetic variations in the Mdr1 gene, such as in the Collie breed, can significantly alter drug pharmacokinetics.
  • Accurate prediction of drug behavior in specific canine breeds is crucial for safe and effective therapeutic use.

Purpose of the Study:

  • To develop a bottom-up physiologically based pharmacokinetic (PBPK) model for predicting loperamide pharmacokinetics in Collies.
  • To incorporate in vitro-to-in vivo extrapolation (IVIVE) techniques for predicting in vivo drug exposure.
  • To evaluate the model's performance in both wild-type (WT) and Mdr1-deficient (Mu, Δ-Mdr1) Collies.

Main Methods:

  • Development of a breed-specific whole-body PBPK model for Collies using published physiological data.
  • Application of in vitro-to-in vivo extrapolation (IVIVE) to predict loperamide absorption, distribution, metabolism, and elimination (ADME).
  • Utilized the Simcyp Animal Simulator for loperamide IVIVE-PBPK modeling and simulation.

Main Results:

  • The developed PBPK model successfully captured observed plasma concentration-versus-time profiles for loperamide in both WT and Mu Collies.
  • Model predictions for Area Under the Curve (AUC) and maximal plasma concentration (Cmax) showed good agreement with observed values.
  • Predicted Cmax values were within ±25% of observed values for 67% of WT dog doses, and AUC predictions were within 50% for all Mu dog doses.

Conclusions:

  • This study presents the first systematic approach for developing a Collie-specific PBPK model to predict loperamide pharmacokinetics.
  • The model effectively illustrates the impact of the canine Mdr1 genetic variation on drug disposition.
  • The established IVIVE-PBPK framework provides a general workflow for predicting in vivo drug behavior in specific canine breeds.